Ruthigen announces plans to price initial public offering of its stock

Bookrunner Aegis Capital raises funds for clinical trial of RUT58-60

By Devika Patel

Knoxville, Tenn., Aug. 8 - Ruthigen, Inc. will price its initial public offering of common stock with a 45-day greenshoe, according to a Form S-1 filed Thursday with the Securities and Exchange Commission.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used for a planned phase 1/2 clinical trial of RUT58-60, to establish and validate an independent research and developmen and cGMP manufacturing facility and for general corporate purposes, including working capital.

The Santa Rosa, Calif., biopharmaceutical company is a subsidiary of Oculus Innovative Sciences, Inc. The company expects the shares to trade on the Nasdaq under the symbol "RTGN."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.